2024
Effect of intraovarian platelet-rich plasma injection on IVF outcomes in women with poor ovarian response: the PROVA randomized controlled trial
Herlihy N, Cakiroglu Y, Whitehead C, Reig A, Tiras B, Scott R, Seli E. Effect of intraovarian platelet-rich plasma injection on IVF outcomes in women with poor ovarian response: the PROVA randomized controlled trial. Human Reproduction 2024, 39: 1495-1503. PMID: 38725194, DOI: 10.1093/humrep/deae093.Peer-Reviewed Original ResearchPoor ovarian responseControlled ovarian stimulationHistory of poor ovarian responsePremature ovarian insufficiencyPlatelet-rich plasmaPlatelet-rich plasma injectionsMature oocyte yieldRandomized Controlled TrialsPRP injectionEuploid blastocystsOvarian responseOocyte yieldOocyte retrievalIVF outcomesIntraovarian platelet-rich plasmaUniversity-affiliated reproductive centerIVF historyMature oocytesSustained implantationDATE OF FIRST PATIENT’S ENROLMENT:Euploid embryo transferInclusion criteriaPlatelet-rich plasma preparationsPreimplantation genetic testingOvarian reserve tests
2023
Random start ovarian stimulation before gonadotoxic therapies in women with cancer: a systematic review and meta-analysis
Sönmezer M, Şükür Y, Ateş C, Saçıntı K, Sönmezer M, Aslan B, Atabekoğlu C, Özmen B, Oktay K. Random start ovarian stimulation before gonadotoxic therapies in women with cancer: a systematic review and meta-analysis. Reproductive BioMedicine Online 2023, 47: 103337. PMID: 37857156, PMCID: PMC11073797, DOI: 10.1016/j.rbmo.2023.103337.Peer-Reviewed Original ResearchRandom-start ovarian stimulationOvarian stimulationCancer patientsSystematic reviewGonadotrophin consumptionGonadotoxic treatmentNewcastle-Ottawa Quality Assessment ScaleFinal analytical cohortMature oocyte yieldQuality Assessment ScaleNumber of oocytesDuration of stimulationMeta-analysis demonstrateMeta-analysis showNumber of embryosGonadotoxic therapyPrimary outcomeAnalytical cohortOocyte yieldCochrane LibraryAFC ratioAssessment ScaleMII oocytesPatientsCount ratio
2015
Fertility Preservation for Women with Sickle Cell Disease (SCD)
Plowden T, Millan N, Owen C, Healy M, Banks N, Hsieh M, Fitzhugh C, Witmyer J, Peak D, Frankfurter D, DeCherney A, Tisdale J, Wolff E. Fertility Preservation for Women with Sickle Cell Disease (SCD). Blood 2015, 126: 3408. DOI: 10.1182/blood.v126.23.3408.3408.Peer-Reviewed Original ResearchPeripheral blood stem cell transplantationSickle cell diseasePremature ovarian insufficiencyFertility preservationOvarian insufficiencyPatient 3Standard controlled ovarian hyperstimulationBlood stem cell transplantationSerum reproductive hormone levelsCure sickle cell diseaseProspective cohort of womenAntagonist protocol cyclesFertility preservation cyclesSevere sickle cell diseaseMature oocyte yieldStem cell transplantationOral pain medicationVenous thrombotic eventsTransvaginal oocyte retrievalCohort of womenReproductive age womenReproductive hormone levelsCo-morbid conditionsMultiple risk factorsOocyte yield
2010
In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation
Oktay K, Buyuk E, Rodriguez-Wallberg K, Sahin G. In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. Reproductive BioMedicine Online 2010, 20: 634-638. PMID: 20219430, DOI: 10.1016/j.rbmo.2010.01.012.Peer-Reviewed Original ResearchConceptsBreast cancer patientsMature oocyte yieldCancer patientsOvarian stimulationOocyte yieldFertility preservationFertility preservation cyclesMature oocytesCryopreservation cyclesTotal numberSecondary analysisVitro maturationImmature oocytesPatientsIVMEmbryo cryopreservationFertilization rateOocytesStimulationUseful strategyMaturationChemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply